Integra LifeSciences Holdings C

Valuation Analysis

About the Company

Integra LifeSciences Holdings C en bref

Integra LifeSciences Holdings C (IART) is currently trading at 15,33 € with a market capitalization of 1,2 Md €. The 52-week range spans from 7,58 € to 15,92 €; the current price is 3.7% below the yearly high. Year-over-year revenue growth stands at +2.4%.

💰 Dividende

Integra LifeSciences Holdings C currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

7 analystes évaluent Integra LifeSciences Holdings C (IART) au consensus : Conserver. L'objectif de cours moyen est de 15,19 €, soit un potentiel de -0.86% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 9,59 € à 23,54 €.

Integra LifeSciences Holdings C : la thèse d'investissement en détail

Integra LifeSciences Holdings C (IART) operates in the Healthcare — specifically Medical Devices — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario baissier

Revenue growth has slowed to just 2.4%, which is below nominal GDP — the business is no longer outgrowing the broader economy. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. Short interest sits at 14.15% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Valorisation en contexte

With a PEG ratio of 0.67, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.

À surveiller

• The share is trading at 92.9% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

The data points to market-like volatility, elevated short interest (14.15%), higher leverage relative to equity.

Trading Data

Related Stocks in the Same Sector

Where can I buy Integra LifeSciences Holdings C?

Compare top-rated brokers — low fees, trusted providers, fully regulated.